Sunday, May 09, 2021 9:22:15 AM
Yes, Fauci did.... he moved banned "gain of function" research from the US to the Wuhan Lab and provided millions in funding. COVID-19 is not a natural virus, it was genetically spliced using SARS, HIV and MERS. The gain of function development was done so humans would be infected by it. Anthony Fauci could be facing crimes against humanity charges along with big pharma executives.
In a 263-page document, written by People’s Liberation Army scientists and senior Chinese public health officials and obtained by the US State Department during its investigation into the origins of COVID-19, PLA scientists note how a sudden surge of patients requiring hospitalization during a bioweapon attack “could cause the enemy’s medical system to collapse,” according to The Weekend Australian (a subsidiary of News Corp).
It suggests that SARS coronaviruses could herald a “new era of genetic weapons,” and noted that they can be “artificially manipulated into an emerging human disease virus, then weaponized and unleashed in a way never seen before.”
And as we noted in March, the US National Institutes of Health (NIH) – headed by Dr. Anthony Fauci, “had funded a number of projects that involved WIV scientists, including much of the Wuhan lab’s work with bat coronaviruses.”
In 2017, Fauci’s agency resumed funding a controversial grant to genetically modify bat coronaviruses in Wuhan, China without the approval of a government oversight body, according to the Daily Caller. For context, in 2014, the Obama administration temporarily suspended federal funding for gain-of-function research on bat coronaviruses. Four months prior to that decision, the NIH effectively shifted this research to the Wuhan Institute of Virology (WIV) via a grant to nonprofit group EcoHealth Alliance, headed by Peter Daszak.
The NIH’s first $666,442 installment of EcoHealth’s $3.7 million grant was paid in June 2014, with similar annual payments through May 2019 under the “Understanding The Risk Of Bat Coronavirus Emergence” project.
Notably, the WIV “had openly participated in gain-of-function research in partnership with U.S. universities and institutions” for years under the leadership of Dr. Shi ‘Batwoman’ Zhengli.
In a 263-page document, written by People’s Liberation Army scientists and senior Chinese public health officials and obtained by the US State Department during its investigation into the origins of COVID-19, PLA scientists note how a sudden surge of patients requiring hospitalization during a bioweapon attack “could cause the enemy’s medical system to collapse,” according to The Weekend Australian (a subsidiary of News Corp).
It suggests that SARS coronaviruses could herald a “new era of genetic weapons,” and noted that they can be “artificially manipulated into an emerging human disease virus, then weaponized and unleashed in a way never seen before.”
And as we noted in March, the US National Institutes of Health (NIH) – headed by Dr. Anthony Fauci, “had funded a number of projects that involved WIV scientists, including much of the Wuhan lab’s work with bat coronaviruses.”
In 2017, Fauci’s agency resumed funding a controversial grant to genetically modify bat coronaviruses in Wuhan, China without the approval of a government oversight body, according to the Daily Caller. For context, in 2014, the Obama administration temporarily suspended federal funding for gain-of-function research on bat coronaviruses. Four months prior to that decision, the NIH effectively shifted this research to the Wuhan Institute of Virology (WIV) via a grant to nonprofit group EcoHealth Alliance, headed by Peter Daszak.
The NIH’s first $666,442 installment of EcoHealth’s $3.7 million grant was paid in June 2014, with similar annual payments through May 2019 under the “Understanding The Risk Of Bat Coronavirus Emergence” project.
Notably, the WIV “had openly participated in gain-of-function research in partnership with U.S. universities and institutions” for years under the leadership of Dr. Shi ‘Batwoman’ Zhengli.
Recent PFE News
- Pfizer Declares Second-Quarter 2026 Dividend • Business Wire • 04/22/2026 08:45:00 PM
- Pfizer Showcases Oncology Innovation and Next-Generation Pipeline at ASCO 2026 • Business Wire • 04/21/2026 03:51:00 PM
- U.S. FDA Grants Priority Review to sBLA for PADCEV™ + Keytruda® as Perioperative Treatment for Muscle-Invasive Bladder Cancer Regardless of Cisplatin Eligibility • PR Newswire (US) • 04/20/2026 10:45:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/17/2026 05:16:32 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/16/2026 08:31:02 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 04/10/2026 05:10:35 PM
- Pfizer Invites Shareholders to View and Listen to Webcast of April 23 Virtual 2026 Annual Meeting of Shareholders • Business Wire • 04/09/2026 02:00:00 PM
- Telix Strengthens Board with Additional Director Appointments • GlobeNewswire Inc. • 04/08/2026 10:44:20 PM
- AI-Enhanced Robotics in Pharma Manufacturing Signals Major Efficiency, Margin Expansion Opportunities • GlobeNewswire Inc. • 04/07/2026 12:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/01/2026 09:52:46 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/31/2026 12:22:26 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/31/2026 12:21:25 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/31/2026 12:20:23 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/31/2026 12:19:22 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/31/2026 12:19:20 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/31/2026 12:18:19 AM
- Pfizer Invites Public to View and Listen to Webcast of May 5 Conference Call with Analysts • Business Wire • 03/24/2026 02:00:00 PM
- Pfizer and Valneva Announce Lyme Disease Vaccine Candidate Demonstrates Strong Efficacy in Phase 3 VALOR Trial • Business Wire • 03/23/2026 10:45:00 AM
- Pfizer Recommends Shareholders Reject the Mini-Tender Offer by Tutanota LLC • Business Wire • 03/20/2026 08:30:00 PM
- Pfizer’s TALZENNA combination shows progress against prostate cancer • IH Market News • 03/19/2026 02:44:13 PM
- TALZENNA Plus XTANDI Significantly Improves Radiographic Progression-Free Survival in Metastatic Prostate Cancer • Business Wire • 03/19/2026 10:45:00 AM
- Pfizer Announces Positive Topline Phase 2 Results for Next-Generation CDK4 Inhibitor, Atirmociclib, in Second-Line Metastatic Breast Cancer • Business Wire • 03/17/2026 10:45:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/16/2026 09:45:46 PM
